SCHEMBL16396241

SCHEMBL16396241

N#Cc1cccc(S(=O)(=O)c2cccc(NC(=O)O)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
LMNA P02545 3/20 0.51
MAPT P10636 3/20 0.51
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HTT P42858 2/20 0.50
GAA P10253 2/20 0.50
USP2 O75604 1/20 0.50
HPGD P15428 1/20 0.50
NAMPT P43490 1/20 0.48
KCNJ6 P48051 1/20 0.47
KCNJ5 P48544 1/20 0.47
KCNJ3 P48549 1/20 0.47
MAPK1 P28482 2/20 0.47
HSD17B10 Q99714 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PGR P06401 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26273989 0.87 LMNA (0.54) SMN1; SMN2LMNAMAPTALDH1A1MEN1
SCHEMBL11644560 0.85 CA1 (0.64) SMN1; SMN2LMNAMAPTALDH1A1MEN1
SCHEMBL4901069 0.85 MAPT (0.68) SMN1; SMN2LMNAMAPTALDH1A1MEN1
Fluoride SCHEMBL11786822 0.83 MAPT (0.66) SMN1; SMN2LMNAMAPTALDH1A1MEN1
SCHEMBL11643227 0.82 SMN1; SMN2 (0.61) SMN1; SMN2LMNAMAPTALDH1A1MEN1
SCHEMBL28225535 0.81 RORC (0.55) SMN1; SMN2LMNAMAPTALDH1A1MEN1
SCHEMBL27910606 0.80 HTR6 (0.54) LMNAMAPTALDH1A1NAMPTPGR
SCHEMBL11641677 0.79 LMNA (0.54) SMN1; SMN2LMNAMAPTALDH1A1MEN1
SCHEMBL11645791 0.76 NAMPT (0.58) SMN1; SMN2LMNAMAPTALDH1A1MEN1
SCHEMBL11646510 0.76 CA1 (0.63) SMN1; SMN2LMNAMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562912-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2020-02-18 US disclosed
EP-3004057-B1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS C&C RES LAB (KR) 2018-07-25 EP disclosed
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2016-04-21 US disclosed
EP-3004057-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C Research Laboratories (KR) 2016-04-13 EP disclosed
WO-2014196793-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2014-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF STAT3, JAK2, STAT5A SMN1; SMN2 3612/4885LMNA 4154/4885MAPT 4514/4885
US-10562912-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, STAT5A SMN1; SMN2 3612/4885LMNA 4154/4885MAPT 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.